Global innovator in drug delivery platforms Lexaria
Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and
Drug Administration (“FDA”), for the first time ever, has authorized the
marketing of oral nicotine products through the Modified Risk Tobacco Product
pathway. According to the update, this pathway includes product categories that
could benefit from Lexaria’s technology. The FDA-authorized product format is
in the tobacco pouch category, similar to a mini tea-bag that is held in the
mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there
is no need to spit. Significantly, because there is no combustion, heating or
vaporization of the tobacco pouch during use, as well as FDA-accepted
scientific evidence that included long-term epidemiological studies in
association with this approval, claims of a lower risk of mouth cancer, stroke,
lung disease, heart disease, emphysema and chronic bronchitis than cigarettes
are permitted by the FDA. “Lexaria applauds this informed and forward-looking
decision by the FDA to recognize improvements in delivery formats that are
being made by industry,” Lexaria Bioscience Corp. CEO Chris Bunka said in the
news release. “Lexaria realized long ago that DehydraTECH(TM) could empower
alternative nicotine product formats and as a result our delivery technology
which is already patented in the U.S. and patent pending around the world for
enhanced oral nicotine delivery.”
To view the full press releases, visit http://ibn.fm/l7EVp
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in
drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology
changes the way active pharmaceutical ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher effectiveness
for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces
time of onset and masks unwanted tastes for orally administered bioactive
molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory
drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed
DehydraTECH to multiple companies in the cannabis industry for use in
cannabinoid beverages, edibles and oral products, as well as to a world-leading
tobacco producer for the development of smokeless, oral-based nicotine
products. Lexaria operates a licensed, in-house research laboratory and holds a
robust intellectual property portfolio with 16 patents granted and over 60
patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment